Movatterモバイル変換

[0]ホーム
URL:

Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Nature Publishing Group full text link Nature Publishing Group Free PMC article
Full text links

Actions

Share

.2016:2:15025.
doi: 10.1038/npjbcancer.2015.25. Epub 2016 Jan 20.

Tumor-associated macrophages: unwitting accomplices in breast cancer malignancy

Affiliations

Tumor-associated macrophages: unwitting accomplices in breast cancer malignancy

Carly Bess Williams et al. NPJ Breast Cancer.2016.

Abstract

Deleterious inflammation is a primary feature of breast cancer. Accumulating evidence demonstrates that macrophages, the most abundant leukocyte population in mammary tumors, have a critical role at each stage of cancer progression. Such tumor-associated macrophages facilitate neoplastic transformation, tumor immune evasion and the subsequent metastatic cascade. Herein, we discuss the dynamic process whereby molecular and cellular features of the tumor microenvironment act to license tissue-repair mechanisms of macrophages, fostering angiogenesis, metastasis and the support of cancer stem cells. We illustrate how tumors induce, then exploit trophic macrophages to subvert innate and adaptive immune responses capable of destroying malignant cells. Finally, we discuss compelling evidence from murine models of cancer and early clinical trials in support of macrophage-targeted intervention strategies with the potential to dramatically reduce breast cancer morbidity and mortality.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The progression of breast cancer can be highlighted through the relationship between the primary tumor and specialized immune cells, including monocytes and TAMs. The primary tumor is made up of a heterogeneous population of breast cancer cells, which can recruit monocytes from the blood stream via secretion of cytokines, CCL2 and CSF1. Once monocytes are recruited to the primary tumor, these cells can then in turn differentiate into TAMs. The TAMs can secrete EGF that binds to EGFR on the breast cancer cells. This positive-feedback loop between TAMs and breast cancer cells is essential for the progression and migration of breast cancer cells to distant sites of metastasis. Along with TAMs providing EGF to the breast cancer cells, they also secrete VEGF and IL-8 into the TME, which stimulates (1) angiogenesis; the formation of new blood vessels around the primary tumor that deliver oxygen and nutrients. Additionally, TAMs induce breast cancer cells to (2) migrate and enter the blood stream, allowing them to travel to distant metastatic sites in the body. Breast cancer cells can migrate to premetastatic niches in distal organs that harbor a set of TAMs, which allows for (3) metastasis to occur. Common sites of metastasis include lung and bone, pictured here, as well as brain, liver, and lymph nodes. TAMs found in the premetastatic niche of metastatic sites display different receptors than the TAMs interacting with the primary breast tumor. Breast cancer cells can interact with these premetastatic niche TAMs within the metastatic site and the positive-feedback loop that occurs between the primary tumor and TAMs starts anew. EGF, epidermal growth factor; TAM, tumor-associated macrophages; TME, tumor microenvironment.
Figure 2
Figure 2
Modes of TAM-mediated immunosuppression. Upon recruitment to mammary tumors, exposure to TME-derived factors skew macrophage function from tumoricidal to tumorigenic. Hypoxia, growth factors, and immunosuppressive cytokines present in the TME polarize tumor-infiltrating macrophages toward a trophic phenotype, resulting in the loss of cytotoxic ability and acquisition of tissue-repair/growth capability. Concomitantly, the metabolism ofL-arginine, production of immunosuppressive cytokines and expression of inhibitory T-cell checkpoint regulators by TAMs serve to inhibit T-cell activation and subsequent tumor killing. Finally, through the production of potent chemoattractants, TAMs recruit cells which further suppress antitumor immunity including MDSCs, immature DCs, and Tregs. Together, these processes culminate to circumvent immunosurveillance and tumor-reactive immunity capable of eliminating mammary tumors. TAM, tumor-associated macrophages; TME, tumor microenvironment.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Paget, S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev 8, 98 (1989). - PubMed
    1. Kroemer, G. et al. Natural and therapy-induced immunosurveillance in breast cancer. Nat. Med. 21, 1128–1138 (2015). - PubMed
    1. Koebel, C. M. et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450, 903–907 (2007). - PubMed
    1. Denkert, C. et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J. Clin. Oncol. 28, 105–113 (2010). - PubMed
    1. Ali, H. R. et al. Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. Ann. Oncol. 25, 1536–1543 (2014). - PubMed

Grants and funding

LinkOut - more resources

Full text links
Nature Publishing Group full text link Nature Publishing Group Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

[8]ページ先頭
©2009-2025 Movatter.jp